DiaMedica Therapeutics
DMAC
33 hedge funds and large institutions have $28.4M invested in DiaMedica Therapeutics in 2020 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 12 increasing their positions, 2 reducing their positions, and 3 closing their positions.
500% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 2
333% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 3
43% more funds holding
Funds holding: 23 → 33 (+10)
35% more capital invested
Capital invested by funds: $21M → $28.4M (+$7.36M)
14.33% more ownership
Funds ownership: 21.46% → 35.8% (+14%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.23M |
| 2 |
CA
Corriente Advisors
Fort Worth,
Texas
|
+$2.8M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$2.53M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$2.2M |
| 5 |
MS
Maven Securities
St Helier,
Jersey
|
+$1.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair & Company
Chicago,
Illinois
|
-$69K |
| 2 |
Renaissance Technologies
New York
|
-$46K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$4K |
| 4 |
BlackRock
New York
|
-$3.89K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| $8K | +$42 | +8 | +0.4% |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| $6K | +$7.32K | +1,383 | New |
|
28
Federated Hermes
Pittsburgh,
Pennsylvania
| $3K | +$3.31K | +625 | New |
|
|
GCM
29
Gables Capital Management
Miami,
Florida
| $2K | +$2.21K | +417 | +334% |
|
|
NFSG
30
Newbridge Financial Services Group
Boca Raton,
Florida
| $2K | +$2.26K | +427 | New |
|
31
Bank of Montreal
Toronto,
Ontario, Canada
| $1K | – | – | – |
|
|
32
William Blair & Company
Chicago,
Illinois
| – | -$69K | -10,000 | Closed |
|
|
33
UBS Group
Zurich,
Switzerland
| – | -$4K | -589 | Closed |
|
|
34
Bank of America
Charlotte,
North Carolina
| – | -$1K | -73 | Closed |
|
DMAC Hedge Fund Activity: Q3 2020 in Review
33 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in DiaMedica Therapeutics (DMAC) for Q3 2020, worth a combined $28.4M — up 35% from $21M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new DMAC positions and 3 closed out — a net gain of 10 holders — while 12 added to existing stakes and 2 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $4.23M. The largest seller was William Blair & Company, exiting entirely with an estimated $69K sold.
- 33 institutional investors held DiaMedica Therapeutics (DMAC) as of Q3 2020, up from 23 in Q2 2020.
- Funds reported $28.4M of DiaMedica Therapeutics stock for Q3 2020, up 35% quarter-over-quarter.
- 13 funds opened new DiaMedica Therapeutics positions in Q3 2020 and 3 closed out, a net change of +10 holders.
- The largest DiaMedica Therapeutics buyer in Q3 2020 was Point72 Asset Management, an estimated $4.23M added.
- The largest DiaMedica Therapeutics seller in Q3 2020 was William Blair & Company, an estimated $69K sold.
Based on aggregated 13F filings for Q3 2020.